Bicycle Therapeutics and Cancer Research UK Named Best Partnership Alliance of the Year at 2017 Scrip Awards


Bicycle Therapeutics and Cancer Research UK today announced that their collaboration has secured a prestigious Scrip Award, winning 2017’s Best Partnership Alliance.

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform,is partnering with Cancer Research UK, the world’s largest cancer charity, to develop its lead candidate, BT1718, in patients with advanced poorly treated cancers. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MTP), which is highly expressed in many solid tumors, including triple negative breast cancer and non-small cell lung cancer. The program will enter the clinic in early 2018.

Dr. Nigel Blackburn, Cancer Research UK’s director of drug development, said: “We’re thrilled to be recognized for our valuable strategic partnership with Bicycle Therapeutics. Our collaborative partnerships with industry help bring the most promising new treatments to patients and BT1718 is a potentially transformative drug that could be used to tackle many different cancers.

“Finding new ways to target hard to treat cancers is a crucially important area of research and through this collaboration, we hope we can speed up the development of therapies for patients who urgently need new treatment options.”

Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer, said: “We are delighted to receive this prestigious award, which highlights the genuinely collaborative nature of our work with Cancer Research UK. This innovative alliance provides us with an optimal approach for exploring the potential of the Bicycle platform, and we look forward to continuing our work as we move BT1718 into clinical development in 2018.”

Also at the Scrip Awards, Dr. Lee was honored as “Executive of the Year for companies valued below $1 billion” for his dynamic leadership in guiding Bicycle towards the achievement of multiple milestones, including the signing of several important partnerships and a £45 million Series B financing.

Click here for full press release

Contact us


(+44) 1223 496 000

Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom

Press Enquiries

01223 813 557

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
; ;